Gastroenterology
Volume 126, Issue 5 , Pages 1477-1480 , May 2004

Are patients with elevated liver tests at increased risk of drug-induced liver injury?

  • Mark W Russo

      Affiliations

    • Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA
    • ,
  • Paul B Watkins

      Affiliations

    • Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA
    • Corresponding Author InformationAddress requests for reprints to: Paul B. Watkins, M.D., University of North Carolina, CB #7600, General Clinical Research Center 3005 APCF, 101 Manning Drive, Chapel Hill, North Carolina 27514 USA; fax: (919) 966-1576
    • Dr. Watkins is a paid consultant for Johnson &Johnson-Merck.

References 

  1. Zimmerman HJ. Hepatotoxicity (the adverse effects of drugs and other chemicals on the liver). 2nd ed.. Baltimore, MD: Lippincott; 1999;
  2. Sadaphal P, Astermorski J, Graham NM, Sheely L, Bonds M, Madison A, et al. Isoniazid preventive therapy, hepatitis C virus infection, and hepatotoxicity among injection drug users infected with Mycobacterium tuberculosis. Clin Infect Dis. 2001;33:1687–1691
  3. Patel PA, Voigt MD. Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States. Am J Gastroenterol. 2002;97:1198–1203
  4. Wu JC, Lee SD, Yeh PF, Chan CY, Wang YJ, Huang YS, et al. Isoniazid-rifampin-induced hepatitis in hepatitis B carriers. Gastroenterology. 1990;98:502–504
  5. Wit WNMF, Weverling GJ, Weel J, Jurriaans S, Lange JMA. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis. 2002;186:23–31
  6. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283:74–80
  7. den Brinker M, Wit FWNM, Wertheim-van Dillen PME, Jurriaans S, Weel J, Leeuwen RV, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS. 2000;14:2895–2902
  8. Ungo JR, Jones D, Ashkin D, Hollender ES, Bernstein D, Albanese AP, et al. Antituberculosis drug-induced hepatotoxicity.The role of hepatitis C virus and the human immunodeficiency virus. Am J Respir Crit Care Med. 1998;157:1871–1876
  9. Kontorinis N, Dieterich D. Hepatotoxicity of antiretroviral therapy. AIDS Rev. 2003;5:36–43
  10. Felker BL, Sloan KL, Dominitz JA, Barnes RF. The safety of valproic acid used for patients with hepatitis C infection. Am J Psychiatry. 2003;160:174–178
  11. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology. 2004;126:1287–1292
  12. Russo MW, Jacobson IM. How to use statins in patients with chronic liver disease. Cleveland Clin J Med. 2004;71:58–62
  13. Tolman KG. The liver and lovastatin. Am J Cardiol. 2002;89:1374–1380

PII: S0016-5085(04)00483-4

doi: 10.1053/j.gastro.2004.03.030

Gastroenterology
Volume 126, Issue 5 , Pages 1477-1480 , May 2004

Article Tools